Evidence map›Paper›PMID 32420447›Full record

ArticleInternational journal of cardiology. Heart & vasculature2020

Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction.

Anna Bobenko, André Duvinage, Meinhard Mende, Volker Holzendorf, Kathleen Nolte, Christoph Herrmann-Lingen, Lutz Binder, Hans-Dirk Düngen, Gerd Hasenfuss, Burkert Pieske and 2 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna BobenkoCharité Universitätsmedizin Berlin, Department of Cardiology Internal Medicine and Cardiology, Berlin, Germany.
André DuvinageTechnische Universität München, Department of Prevention, Rehabilitation and Sports Medicine, Munich, Germany.
Meinhard MendeUniversity of Leipzig, Clinical Trial Centre (KKS), Leipzig, Germany.
Volker HolzendorfUniversity of Leipzig, Clinical Trial Centre (KKS), Leipzig, Germany.
Kathleen NolteUniversity of Göttingen Medical Centre, Clinic for Cardiology and Pneumology, Göttingen, Germany.
Christoph Herrmann-LingenDZHK (German Centre for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.
Lutz BinderDZHK (German Centre for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.
Hans-Dirk DüngenCharité Universitätsmedizin Berlin, Department of Cardiology Internal Medicine and Cardiology, Berlin, Germany.
Gerd HasenfussUniversity of Göttingen Medical Centre, Clinic for Cardiology and Pneumology, Göttingen, Germany.
Burkert PieskeCharité Universitätsmedizin Berlin, Department of Cardiology Internal Medicine and Cardiology, Berlin, Germany.
Rolf WachterUniversity of Göttingen Medical Centre, Clinic for Cardiology and Pneumology, Göttingen, Germany.
Frank EdelmannCharité Universitätsmedizin Berlin, Department of Cardiology Internal Medicine and Cardiology, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHigh prevalence and lack of pharmacological treatment are making heart failure with preserved ejection fraction (HFpEF) a growing public health problem. No algorithm for the screening of asymptomatic patients with risk for HFpEF exists to date. We assessed whether HFA/ESC 2007 diagnostic criteria for HFpEF are helpful to investigate the cardiovascular outcome in asymptomatic patients. METHODS AND

resultsWe performed an analysis of the Diagnostic Trial on Prevalence and Clinical Course of Diastolic Dysfunction and Heart Failure (DIAST-CHF) that recruited patients with cardiovascular risk factors. All patients underwent a comprehensive diagnostic workup at baseline. Asymptomatic patients with preserved LVEF (>50%) were selected and classified according to HFA/ESC surrogate criteria for left ventricular elevated filling pressure (mean E/e' >15 or E/e' >8 and presence of either NT-proBNP > 220 ng/l, BNP > 200 ng/l or atrial fibrillation) into elevated filling pressure (FPe) or controls. Cardiovascular hospitalizations and all-cause death were assessed for both groups over a 10-year-follow-up.851 asymptomatic patients (age 65.5 ± 7.6 years, 44% female) were included in the analysis. FPe-patients were significantly older (p < 0.001), more often female (p = 0.003) and more often had a history of coronary artery disease, atrial fibrillation and renal dysfunction (p < 0.001, respectively) compared to controls. Incidence of death was significantly higher in the FPe group after a 10-year follow-up (p < 0.001), whereas cardiovascular hospitalization did not differ between groups.

conclusionAsymptomatic patients that fulfill HFA/ESC diagnostic criteria for HFpEF are at higher risk of symptomatic HFpEF and have a worse 10-year-outcome than those who do not fulfill criteria.

Indexed as

AsymptomaticElevated left ventricular filling pressureHeart failure with preserved ejection fractionLeft ventricular diastolic dysfunctionOutcome

Identifiers

PMID32420447
PMCPMC7218096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.